In Loss For Boston Scientific, Panel Upholds Obviousness Findings

Mealey's (March 21, 2022, 1:06 PM EDT) -- WASHINGTON, D.C. — A final written decision by the Patent Trial and Appeal Board that all claims of a patented Boston Scientific Neuromodulation Corp. patent are invalid as obvious was not...
To view the full article, register now.